American Diabetes Association. 9.Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(suppl 1):S111-S124.
2.
Ampudia-BlascoFJPalancaATrilloJLNavarroJRealJT.Therapeutic inertia in patients with type 2 diabetes treated with non-insulin agents. J Diabetes Complications. 2021;35(3):107828. doi:10.1016/j.jdiacomp.2020.107828
3.
AndersonJE.Combining glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors to target multiple organ defects in type 2 diabetes. Diabetes Spectr. 2020;33(2):165-174.
KhuntiKGomesMBPocockS, et al. Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab. 2018;20(2):427-437. doi:10.1111/dom.13088
6.
KhuntiSKhuntiKSeiduS.Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. Ther Adv Endocrinol Metab. 2019;10:2042018819844694. Published May 3, 2019. doi:10.1177/2042018819844694
7.
LajaraR.Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes. Postgrad Med. 2019;131(8):555-565. doi:10.1080/00325481.20 19.1670017
8.
ZhuNAHarrisSB.Therapeutic inertia in people with type 2 diabetes in primary care: a challenge that just won’t go away. Diabetes Spectr. 2020;33(1):44-49.
